AI automation, and more skilled staff are needed to ensure cancer patients can access potentially life-saving CAR T therapies.

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.

SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

Automated cell therapy manufacturing pioneer Cellares has hit a key milestone, gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Cell Therapy Manufacturers · GlobeNewswire Inc. Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Since the first FDA approval of a CAR T-cell therapy in 2017, 1 the cell and gene therapy field has seen substantial market expansion. Manufacturing alone is projected to grow at an annual rate of 30% ...